Evidence map›Paper›PMID 28498441›Full record

ArticleInternational journal of oncology2017

Radiolabeling of VEGF165 with 99mTc to evaluate VEGFR expression in tumor angiogenesis.

Filippo Galli, Marco Artico, Samanta Taurone, Isabella Manni, Enrica Bianchi, Giulia Piaggio, Bruce D Weintraub, Mariusz W Szkudlinski, Enzo Agostinelli, Rudi A J O Dierckx and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. The prognostic value of [European journal of nuclear medicine and molecular imaging · 2018
    Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Filippo GalliNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Rome, Italy.
Marco ArticoDepartment of Sensory Organs, 'Sapienza' University of Rome, Rome, Italy.
Samanta TauroneDepartment of Sensory Organs, 'Sapienza' University of Rome, Rome, Italy.
Isabella ManniSAFU UOSD, Department of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy.
Enrica BianchiDepartment of Sensory Organs, 'Sapienza' University of Rome, Rome, Italy.
Giulia PiaggioSAFU UOSD, Department of Research, Advanced Diagnostics and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy.
Bruce D WeintraubTrophogen Inc., Rockville, MD, USA.
Mariusz W SzkudlinskiTrophogen Inc., Rockville, MD, USA.
Enzo AgostinelliDepartment of Biochemical Sciences 'A. Rossi Fanelli', 'Sapienza' University of Rome, Rome, Italy.
Rudi A J O DierckxDepartment of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Alberto SignoreNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Rome, Italy.
Sapienza University of Rome · ITTrophogen (United States) · USUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiogenesis is the main process responsible for tumor growth and metastatization. The principal effector of such mechanism is the vascular endothelial growth factor (VEGF) secreted by cancer cells and other components of tumor microenvironment. Radiolabeled VEGF analogues may provide a useful tool to noninvasively image tumor lesions and evaluate the efficacy of anti-angiogenic drugs that block the VEGFR pathway. Aim of the present study was to radiolabel the human VEGF165 analogue with 99mTechnetium (99mTc) and to evaluate the expression of VEGFR in both cancer and endothelial cells in the tumor microenvironment. 99mTc-VEGF showed in vitro binding to HUVEC cells and in vivo to xenograft tumors in mice (ARO, K1 and HT29). By comparing in vivo data with immunohistochemical analysis of excised tumors we found an inverse correlation between 99mTc-VEGF165 uptake and VEGF histologically detected, but a positive correlation with VEGF receptor expression (VEGFR1). Results of our studies indicate that endogenous VEGF production by cancer cells and other cells of tumor microenvironment should be taken in consideration when performing scintigraphy with radiolabeled VEGF, because of possible false negative results due to saturation of VEGFRs.

Indexed as

Angiogenesis InhibitorsAnimalsGene Expression Regulation, NeoplasticHT29 CellsHumansHuman Umbilical Vein Endothelial CellsMiceNeovascularization, PathologicTechnetiumTumor MicroenvironmentVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Xenograft Model Antitumor AssaysAngiogenesis InhibitorsTechnetiumTechnetium-99Vascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1VEGFA protein, human

Identifiers

PMID28498441
PMCPMC6903896
OpenAlexW2613423781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.